BBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BridgeBio Pharma Inc (BBIO) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 to invest. The company has strong growth potential driven by its innovative pipeline, positive analyst sentiment, and robust revenue growth. Despite short-term price volatility, the long-term outlook is favorable.
The technical indicators are neutral to slightly bearish in the short term. The RSI is at 47.669, indicating no clear overbought or oversold conditions. The MACD histogram is positive at 0.535, showing a contracting bullish momentum. The stock is trading near its pivot level of 68.689, with key support at 63.671 and resistance at 73.706. However, the recent price drop of -4.78% in the regular market and -2.05% in pre-market suggests short-term weakness.
Strong growth in Attruby sales and positive Phase III infigratinib data in achondroplasia. Multiple analysts have raised price targets, with the highest at $125, citing the company's growth potential and product pipeline.
The stock experienced a significant price drop of -4.78% in the regular market and -2.05% in pre-market, indicating short-term bearish sentiment. Net income and EPS have declined YoY, reflecting ongoing operational losses.
In Q4 2025, revenue increased significantly by 2521.18% YoY to $154.18M, driven by strong product sales. However, net income dropped by -27.24% YoY to -$192.86M, and EPS fell by -28.57% YoY to -1. Gross margin improved to 94.74%, up 46.72% YoY, showcasing operational efficiency despite losses.
Analysts are overwhelmingly positive on BBIO, with multiple firms raising their price targets recently. The highest target is $125, and the lowest is $81, with an average target around $95-$100. Analysts highlight the company's accelerating product launches, strong sales growth, and promising drug pipeline as key drivers for future growth.
